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This keynote review outlines the rationale, study design, and methods for
cognitive safety assessment during clinical drug development, as well as
strategies for interpreting and communicating cognitive risk.
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Cognitive impairment is increasingly recognised as an important potential
adverse effect of medication. However, many drug development
programmes do not incorporate sensitive cognitive measurements. Here,
we review the rationale for cognitive safety assessment, and explain
several basic methodological principles for measuring cognition during
clinical drug development, including study design and statistical analysis,
from Phase I through to postmarketing. The crucial issue of how cognition
should be assessed is emphasized, especially the sensitivity of
measurement. We also consider how best to interpret the magnitude of any
identified effects, including comparison with benchmarks. We conclude
by discussing strategies for the effective communication of cognitive risks.
Introduction
Assessing cognitive safety, in other words the impact of clinical treatments on the ability to
perceive, process, understand, and store information, make decisions and produce appropriate
responses, is an issue whose importance is increasingly recognised by the pharmaceutical
industry, regulators, clinicians, and the public. In some cases (e.g., first-generation antihista-
mines), marked cognitive-impairing effects were established many years ago, and warnings
relating to possible sedation routinely appear on labelling [1]. More recently, there has been
widespread concern about possible adverse effects of several commonly used drugs that, although
not necessarily causing marked sedation, are likely to have important cognitive effects. For
example, several epidemiological cohort studies report that impaired cognitive function is
associated with medications that have anticholinergic activity, particularly when taken in
combination [2]. One large study in older patients reported consistently impaired scores on
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scale) in those using medication with definite anticholinergic
activity, after adjusting for several confounders [3]. Other studies
reported that the use of anticholinergics is associated with in-
creased risk of mild cognitive impairment (MCI) [4], and even with
dementia in a dose-dependent fashion [5,6].
The above results present a clear cause for concern in older people,
but it is also important to consider the potential impact of cognitive
impairment on wellbeing and everyday function in younger popu-
lations. In the workplace, medication-induced cognitive im-
pairment could result in reduced productivity, or ‘presenteeism’,
and could be dangerous for those who drive or operate machinery as
part of their jobs. At school or university, cognitive impairment
could prevent students from fulfilling their academic potential,
with implications for future competitiveness in the jobs market.
Medication-induced cognitive impairment also raises cause for
concern outside work or study contexts: everyday tasks are likely to
be adversely affected. Driving is one of the best studied of these,
and initiatives such as the DRiving Under the Influence of Drugs,
alcohol and medicines project (DRUID [7]) have highlighted clas-
ses of medicine that are likely to induce cognitive impairment,
based on a review of the pharmacological, epidemiological, and
experimental psychopharmacological literature. Laboratory stud-
ies examining alcohol administration (which is well known to
impair driving performance and, therefore, can act as a standard
reference [8]), have highlighted several core cognitive processes
that, if disrupted by a drug, are likely to impair driving ability and
warrant further investigation [9]. Additionally, there is an exten-
sive literature on the effects of common medicines on actual
driving ability, measured using either a specially instrumented
vehicle on a public highway in normal traffic or a driving simulator
[10], which has identified several drug classes that are likely to
increase the risk of road traffic accidents [11].
Whereas driving ability has been particularly well studied, and
warnings not to drive or operate machinery have appeared on
medication labelling for decades, these are not the only important
aspects of everyday function that are likely to be affected if
cognition is disrupted. This issue is well recognised in the literature
on cognitive decline in older individuals, which focuses on activi-
ties of daily living (ADL) [12]. Use of communication devices (and
technology more generally), managing finances, cooking meals,
shopping, navigation, and housework can all be adversely affected
by medication-induced cognitive impairment. Everyday tasks that
are more cognitively demanding (often termed ‘instrumental’
ADLs), such as passing on a message to another person, finding
the way in an unfamiliar place, or taking part in a conversation, are
particularly affected when cognitive ability is disrupted [13], and
are frequently impaired early in the course of cognitive decline.
Such impairment of everyday function substantially reduces qual-
ity of life in patients and is a major contributor to burden on
caregivers [14]. The association between cognitive impairment
and ADL is also pronounced in younger individuals with mental
illness, for example schizophrenia [15] and bipolar disorder [16].
Indeed, several studies have found that in those recovering
from schizophrenia, cognitive performance predicts resumption
of normal function (such as the ability to live independently,
participate in leisure activities, and return to the workplace) better
than symptoms [17].446 www.drugdiscoverytoday.comCognitive impairment clearly represents an important possible
adverse effect of medication. Regulators are likely to demand, and
consumers have the right to be informed about, possible cognitive
risks. However, the degree to which many medications influence
cognitive function remains unknown. In this article, we outline
experimental approaches to determining whether a drug impacts
cognition, discussing: (i) the rationale for assessing cognition
during clinical development; (ii) drug classes likely to affect cog-
nition; (iii) study design, populations and analysis; and (iv) the
importance of using sensitive and comprehensive measurements.
We conclude by considering how to interpret any effects detected,
and strategies for communicating the potential implications of
any findings to regulators and consumers.
Why is it important to assess cognition during clinical
drug development?
Assessment of safety and tolerability (e.g., cardiovascular effects,
changes in liver enzymes, neurological events, etc.) is a crucial
component of early-phase clinical studies. A decision to progress a
candidate compound to later phases depends on the outcome of
these studies. Many central nervous system (CNS) and non-CNS
compounds have the potential to affect cognitive ability detrimen-
tally, and the risks have been highlighted for particular drug
classes [18–21]. Drugs can have multiple pharmacological effects,
some of which are desirable (related to mechanism and/or target of
interest) and some undesirable (‘off-target’, or other pharmacology
leading to adverse effects, such as cognitive dysfunction). If a drug
impairs cognition, this might be related to off-target pharmaco-
logical effects known to impair cognition (e.g., blockade of mus-
carinic, histaminergic, or beta adrenergic receptors). Given the
greater awareness of potential cognitive impairment by regulators
[e.g., US Food and Drug Administration (FDA) advice on statin
risks: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm], as
well as the general public, changes in cognition are increasingly
assessed using objective measures during clinical development to
examine the potential short- and long-term cognitive risks. As
such, assessment of cognitive function can be an integral part of
decision making during clinical development.
Information on the cognitive profile of a compound could be
informative for several reasons and can aid decision making
during clinical development. For example, adverse effects on
cognitive function might be important for: (i) determining
dose–response relationships and selecting safe doses for later
phase development (including the need for titration); (ii) differ-
entiation from competitor drugs in relation to cognitive safety;
(iii) detecting off-target pharmacological effects (i.e., other phar-
macology unrelated to the target of interest); and (iv) assessing
the risk:benefit ratio in relation to the target indication. In
addition, it might also be worthwhile to continue to assess
cognitive safety following approval and marketing through
monitoring of cognitive function as part of routine pharmacov-
igilance, which is increasingly feasible through the use of inter-
net- or app-based assessments. Longer-term monitoring of
cognition might be particularly useful in detecting effects of
drug–drug interactions on cognitive function (Fig. 1), especially
in individuals with multiple co-morbidities (for whom poly-
pharmacy is the norm), because such patients are usually exclud-
ed from clinical trials.
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FIGURE 1
The effect of an antipsychotic and a benzodiazepine drug on reaction times
when administered in combination is greater than the sum of each
separately, indicating a drug–drug interaction. At the time of maximum
impairment (3 h), responses on a choice reaction time test were slowed by
approximately 30 ms by the antipsychotic, approximately 50 ms by the
benzodiazepine [greater than the effect of blood alcohol concentration (BAC)
of 0.05 g/dL, the legal driving limit in many countries], but by approximately
175 ms when these were administered in combination (greater than the
effect of BAC of 0.1 g/dL). If driving at a speed of 100 kph (60 mph), a slowing
of response of approximately 175 ms is equivalent to an increased stopping
distance of approximately 4.9 m (approximately 15 ft), the length of a large
sedan car.
Source: Unpublished data, kindly provided by Otsuka Pharmaceutical Co., Ltd.
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The importance of assessing cognition during clinical develop-
ment is outlined in several FDA guidance documents. For example,
in guidance document UCM126958, published by both the Center
for Drug Evaluation and Research and the Center for Biologics
Evaluation and Research, the FDA highlights the fact that certain
types of adverse effect are likely to go undetected if specific,
sensitive measurements are not used [22]. This document recom-
mends that, when a drug has the potential for such effects,
additional testing or specific assessments will be required. As an
example, it states: ‘for a new drug with recognised CNS effects
(especially sedating effects), sponsors should conduct an assess-
ment of cognitive function, motor skills, and mood’.
More recent FDA guidance provides an even clearer expectation
of cognitive safety assessment during clinical development. The
draft document UCM430374 discusses the evaluation of drug effects
on the ability to operate a motor vehicle (http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM430374.pdf). It states: ‘Beginning with first-in-hu-
man studies, all drugs, including drugs intended for non-CNS
indications, should be evaluated for adverse effects on the CNS
. . . The occurrence of adverse CNS events in even a small number of
phase 1 subjects can indicate the need for more focused studies of
CNS effects. Early testing for CNS effects should generally emphasize
sensitivity over specificity . . . measures of reaction time, divided
attention, selective attention, and memory may be appropriate’.
These regulatory expectations warrant the use of specific, targeted,
and sensitive cognitive safety assessments, because routine moni-
toring will at best underestimate adverse effects and at worst fail to
detect them completely.
The extent to which better monitoring of cognitive outcomes
during drug development can lead to better regulated medicines
is increasingly recognised as important in the wider regulatorycontext. Although assessments establishing the cognitive effects
of drugs have been applied in pharmacological studies since the late
1960s [23], the use of objective tests (as opposed to self-report
measures) has typically not been a requirement of regulatory bodies.
Additionally, those early studies that did use objective cognitive
assessments during the drug development process often focused on
psychomotor function or processing speed, and did not examine
higher-order cognitive processes, such as executive function, social
cognition, or specific components of memory. Consequently, ob-
jective cognitive assessment has not been conducted as consistently
or comprehensively as other types of safety assessment during
clinical development, resulting in uncertainty about the cognitive
impact of many commonly used medicines [24]. Therefore, it is of
clear regulatory interest to incorporate such exercises into ongoing
safety monitoring for currently marketed drugs.
Compounds likely to have a negative impact on
cognition
CNS disorder drugs
Broadly speaking, any drug that is CNS penetrant (i.e., crosses the
blood–brain barrier) can influence cognition through effects on
neurotransmitter systems, such as dopamine, acetylcholine, nor-
adrenaline, glutamate, GABA, histamine, adenosine, and seroto-
nin. More specifically, compounds that boost the function of
specific neurotransmitter systems (e.g., agonists, reuptake inhibi-
tors, or releasers), or block transmission in these systems (e.g.,
antagonists at postsynaptic receptors) might influence cognition.
This includes many compounds developed for neurological dis-
orders, such as epilepsy (i.e., anticonvulsants) and chronic pain, as
well as neuropsychiatric disorders (reviewed in [2,25–30]). The
effects of compounds on cognitive function might be nonlinear;
for example, following an inverted-U function, as observed for
drugs affecting the dopamine system, with either too little or too
much transmission impairing cognition [31]. Such effects are not
simply of academic interest; they are highly relevant for drugs in
development for Parkinson’s disease (i.e., modulators of dopamine
transmission) because it is likely that, although motor symptoms
might be improved, there could be detrimental effects on specific
cognitive processes [32,33]. In the specific case of drugs that
stimulate dopamine D2/D3 receptors, this might include unwant-
ed influences on reward processing and/or impulsivity [34], which
are warning flags for abuse liability.
Non-CNS disorder drugs
Whereas the potential for drugs developed for CNS disorders to
impact cognitive function detrimentally is clear, there are also many
classes of compound developed for non-CNS disorders that confer a
risk of cognitive impairment. Known examples include those de-
veloped for cardiovascular disorders [18,21], obesity [19], oncology
[35,36], genitourinary disorders (e.g., overactive bladder [37,38]),
and allergies [39]. In many cases, it is unclear what processes are
responsible for the deleterious effects on cognition. However, pos-
sible mechanisms include: (i) indirect effects on central neurotrans-
mission; (ii) effects on metabolic function (e.g., glucose, hormones);
(iii) effects on the immune system (e.g., cytokines), which commu-
nicates extensively with the CNS; and (iv) other adverse events (e.g.,
nausea or pain). There is also growing evidence that the integrity
and permeability of the blood–brain barrier can be compromised bywww.drugdiscoverytoday.com 447
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(e.g., diabetes, hypertension, and hypercholesterolemia), inflam-
matory conditions (multiple sclerosis), neurodegenerative diseases
(e.g., Alzheimer’s disease and Parkinson’s disease), infections such
HIV, stroke, traumatic brain injury, and brain tumours [40–42].
Furthermore, the function of the blood–brain barrier can be altered
by certain medications, environmental toxins, and the ageing
process itself [41]. Therefore, there exists the potential for many
new and commonly used drugs to gain access to the brain and have
an unanticipated impact on cognitive function, in both clinical
trials and real-world settings.
Study design and analysis
Epidemiological cohort studies can provide suggestive evidence
that a drug might influence cognition, and often benefit from large
sample sizes resulting in robust statistical inference. However,
experimental clinical studies, in particular double-blind, random-
ised controlled trials (RCTs), should be considered the gold stan-
dard when assessing cognitive safety. Although epidemiological
studies enjoy the benefits of population samples, they are purely
observational and, therefore, can be subject to confounding, by
measured or unmeasured variables, meaning that causal infer-
ences can be difficult. Drawbacks of RCTs include that they are
time consuming to conduct and costly, and that the sample tested
might not be completely representative of the population that will
eventually take the drug. However, ultimately, they provide the
best quality of evidence addressing the question of cognitive safety
and, therefore, represent high value for money.
Phase I
In Phase I trials, cognitive impairment can be considered either at
the level of the individual subject or across groups, alongside other
commonly assessed adverse events. Inferential statistics might or
might not be conducted, but examining patterns in cognitive data
will nonetheless be informative. Cognitive assessments typically
produce continuous measurements, and large databases of norma-
tive scores exist for many commercially available tests; meaning
that the normal range in performance (given a subject’s age and
educational level) can be calculated and used to determine the
likely importance of any observed fluctuations. The standard
approach to cognitive assessment in clinical trials is to take mea-
surements both after drug administration and at baseline (usually
the point of randomisation); including the latter in statistical
analyses improves sensitivity because natural interindividual var-
iability in performance can be accounted for.
One possible approach to declaring a cognitive adverse event
would be if a subject scored within the normal range at baseline,
but following drug administration performance dropped below a
threshold based on the reliable change (RC) index, a metric
derived from the test–retest reliability of a measure [43]. For
cognitive measures, the RC index might need to be adjusted for
practice effects (because people’s scores naturally improve follow-
ing repeated exposure to the same test). Such a categorical ap-
proach might be particularly useful in small Phase I studies, but
inferential statistics would not usually be performed. Isolated
incidents of poor cognitive performance would not necessarily
preclude further drug development, although they might flag up
areas for consideration in later phases.448 www.drugdiscoverytoday.comAlternatively or additionally, cognitive scores before and after
drug administration can be averaged within dose groups and
compared statistically with an active or nonactive comparator.
However, often such comparisons will be limited by poor statisti-
cal sensitivity (see below), even after accounting for baseline
performance, because of the low numbers of subjects typically
included in Phase I studies. As such, results from Phase I cognitive
assessments would usually not be considered conclusive. Depend-
ing on the target indication, if consistent cognitive safety signals
were observed across most or all subjects, this might form part of
the basis of a decision not to progress a compound through the
development pipeline, because of the possibility that the degree of
impairment induced might outweigh the potential clinical bene-
fit. Therefore, checking cognitive effects early in development
could contribute meaningful information to risk management
and go/no-go decisions.
Phases II and III
Cognitive safety is also considered at the group level beyond Phase
I, averaging observations over dozens or hundreds of individuals
per study arm. However, assessing cognitive safety raises some
important design and statistical challenges.
Superiority designs
By its nature, demonstrating cognitive safety requires asking a very
different question to that addressed in standard ‘superiority’ trials,
where the aim is to determine whether a drug performs better than
some comparator (e.g., placebo, a lower dose of the same com-
pound, or an existing in-market drug). A desirable outcome in
superiority trials is to show a difference between the conditions.
The standard (Neyman–Pearson, or frequentist) statistical frame-
work derives a P value: the probability that a pattern of results at
least as extreme as that observed would occur under the null
hypothesis (H0: that the drug under study and the comparator
have the same effect). If the P value falls below a prespecified value
(alpha, the tolerance for the frequency of false positives; conven-
tionally set at 5%), the result is declared significant and H0 is taken
to be rejected. In the frequentist framework, the interpretation of a
significant P value in the context of a superiority trial as supporting
a rejection of the null is logically unambiguous (at a given false
positive tolerance level).
By contrast, demonstrating ‘cognitive safety’ requires asking a
different question: in this case, a desirable result will often be to
conclude that there is no difference between a drug and some
comparator. Adopting a strict interpretation of cognitive safety,
we might wish to ask whether cognitive function while taking a
drug is no worse than if the drug had not been administered. Using
a standard placebo-controlled RCT, failing to show a significant
difference between an active treatment and a nonactive compara-
tor is not, by itself, sufficient to demonstrate cognitive safety. This
is because failing to show a significant difference can be an
ambiguous result in the frequentist statistical framework: absence
of evidence is not necessarily evidence of absence. A nonsignifi-
cant P value can leave the investigator trapped in the logical
straightjacket of a triple negative: a failure (1), to reject (2), the
null (3); a position from which it can be difficult to draw any
meaningful conclusions at all. Therefore, P values cannot, by
themselves, provide evidence in favour of H0, and the notion of
a result being ‘highly nonsignificant’ is logically meaningless [44].
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words, there is genuinely no difference in the cognitive impact of
the drug and the comparator. However, nonsignificance could also
occur even when a difference truly exists, because of low sensitivi-
ty (i.e., a false negative). A common reason for false negatives is
low statistical power; that is, not including enough subjects to
detect an effect of a magnitude considered clinically important.
This must be addressed before the study with a power calculation.
If a minimally important effect size can be specified in advance
(which can itself pose a challenge), then the number of subjects
required to reject the null hypothesis (at given tolerance levels for
false negatives and positives) can be calculated. To provide a
credible demonstration that two conditions do not differ, the
tolerance for false negatives (Type II errors) needs to be controlled
at a sufficiently low rate, just as the tolerance level for false
positives (Type I errors) needs to be controlled in superiority
designs, perhaps also at 5%. This requires large samples. For
example, with the false positive and false negative rates both set
to 5%, testing for an effect of standardised mean difference (SMD,
Cohen’s d) = 0.3 (equivalent to a typical antidepressant effect size
[45]) would require nearly 250 individuals in each arm using a one-
tailed statistic (300 if a two-tailed test were planned, additionally
allowing for the possibility that the drug under study improves
cognition). Assuming that the sensitivity of measurement can be
assured (see section on ‘Measurement of cognition’ below) a
nonsignificant result arising from an adequately powered superi-
ority RCT could be interpreted as indicating that the effect of the
drug in question on cognition is no greater, relative to the com-
parator, than the effect size specified in the power calculation.
Noninferiority designs
Another option, adopting a slightly different interpretation of
cognitive safety, would be to use a ‘noninferiority’ design [46],
in which the drug under study is compared against an active
comparator. Noninferiority trials are often used to establish effi-
cacy in situations when administering placebo would be consid-
ered unethical, for example when an established treatment is
clearly effective and to administer placebo would expose patients
to serious risk. Such designs allow the conclusion that a new drug is
‘no less effective’ (within some margin; see below) than an existing
compound with established efficacy. The logic in the context of a
study on cognitive safety is slightly different. If a comparator drug
has a clearly detrimental influence on cognition, with a well-
established effect size (which might be considered acceptably
low), it can act as a benchmark for the drug under study. If
noninferiority can be demonstrated, it can be concluded that
the drug under study is at least ‘no more detrimental’ (within
some margin) than the active comparator.
In such designs, it is necessary to define a noninferiority margin
(M): the extent to which the drug under study could perform worse
than the active control but still be considered similarly effective (or
harmful, in the case of safety). The starting point for specifying M
is the expected effect of the active comparator relative to placebo,
usually known before the study commences from existing data.
FDA guidance states that M can be ‘no larger than the entire effect
that [the active control] is presumed to have had [relative to a
placebo condition, had it been included]’ (http://www.fda.gov/
downloads/Drugs/Guidances/UCM202140.pdf). Typically, a smal-
ler (i.e., more conservative) estimate of M than this will be used.For example, it might be decided that M should lie within some
percentage of the effect of the active control; alternatively or
additionally, confidence intervals from historical data and/or
clinical judgment might be used. To demonstrate noninferiority,
the 95% confidence interval derived from the contrast of the drug
under study against the active comparator should not overlap with
M.
Although specification of M poses a challenge in conducting
and interpreting such studies, it is arguably no greater than the
challenge in specifying a minimally interesting effect size when
calculating statistical power in a superiority design. However, if a
conservative (i.e., small) M is adopted, large sample sizes might be
required. As well as the potential to demonstrate noninferiority, a
further possibility is that cognitive performance is actually signifi-
cantly better following administration of the drug under study
than the active comparator (similar to a superiority design).
Therefore, it is useful to allow for the additional possibility of
subsequent testing for superiority over the active comparator
(assuming that noninferiority has already been demonstrated),
because this would permit an unambiguous demonstration of
(relative) cognitive safety if statistical significance were achieved.
Hybrid designs
The usual aim in noninferiority studies is to demonstrate that the
drug under study performs no worse that the active comparator,
within the margin, M. This can be achieved using a two-arm design
(http://www.fda.gov/downloads/Drugs/Guidances/UCM202140.
pdf). Such a design assumes that the M can be specified confidently
and appropriately on the basis of historical data (the ‘constancy’
assumption); however, this is not always the case. For example,
data might not be available examining the contrast of the active
comparator against placebo on a particular cognitive measure, or
in a specific population. To facilitate the specification of M in such
cases, it might be useful to incorporate an additional nonactive
(i.e., placebo) comparator condition, allowing for an empirical
estimation.
A convincing result supporting cognitive safety from such a
design would be to demonstrate two effects: (i) the active compar-
ator impairs cognition significantly relative to placebo. This
demonstrates study (and measurement) sensitivity. The placebo
data can then also be used to inform the estimate of M; and (ii)
after M has been specified, the drug under study can then be tested
for noninferiority relative to the active comparator. If both (i) and
(ii) yield significant results, this design enables the conclusion of
noninferiority using an empirically informed M. However, if (i)
fails to achieve significance, this indicates poor study sensitivity,
possibly because the sample size was not sufficiently large, or the
measurement was not sufficiently sensitive.
Further design and analysis considerations
Bayesian analysis
An alternative statistical approach would be to use a Bayesian
procedure, which takes a complementary perspective to the stan-
dard frequentist framework to make inference. Instead of comput-
ing the probability of the observed data, conditioned on H0, the
Bayesian approach computes the probability of the hypothesis in
question, conditioned on the observed data. Note that the term
‘probability’ in the Bayesian framework is applied to hypotheses,
not data, so strictly refers to subjective, not objective probability;www.drugdiscoverytoday.com 449
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A taxonomy of cognition
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FIGURE 2
Commonly assessed components of cognition, broadly split into the domains
of input, storage, and control.
Source: Reproduced, with permission, from Cambridge Cognition.
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is correct. Bayesian inference also requires the specification of
‘priors’; that is, pre-study predictions about experimental data
(although if these are specified weakly, they have little influence
on the conclusions drawn). The observed data are combined with
the priors through application of Bayes’ rule to create a ‘posterior’
estimate, together with a ‘credibility interval’ (the Bayesian equiv-
alent of a confidence interval), which provides the basis for infer-
ence.
The particular value of Bayesian statistics in the assessment of
cognitive safety is that it allows firm conclusions to be drawn
supporting the null hypothesis. Bayesian statistics can also incor-
porate existing data in priors (e.g., the performance of individuals
administered placebo, perhaps established through previous
work), which might allow for a smaller number of subjects to
be tested. Finally, Bayesian inference can allow strong conclusions
to be drawn on the basis of relatively small datasets (see [47] for a
discussion).
Missing data
Missing data are important to consider in any trial, but particularly
in the context of cognitive safety, regardless of the design or
analysis used. If a drug is cognitively impairing, then this effect
itself could conceivably increase the chance that participants will
drop out of the trial, or fail to attend or complete a testing session.
If this occurs, and the probability that a data point is missing
depends on this unobserved value, then the data are ‘missing not
at random’ (MNAR), which could bias subsequent analysis towards
a null effect if a per-protocol analysis is used. In other words, a per-
protocol analysis could fail to detect a genuine cognitive safety
signal (false negative) because the subjects who were most cogni-
tively impaired by the drug were not tested. However, intent-to-
treat analysis with last-observation-carried-forward (LOCF) is also
not an advisable strategy in cognitive safety trials. It will be biased
towards showing no difference when data are MNAR, because
LOCF will tend to underestimate effects. This strategy results in
a more conservative analysis in the context of testing for efficacy,
but a more liberal one in the context of cognitive safety. Thus,
correcting for MNAR data in the context of cognitive safety is not
trivial and careful consideration needs to be given to the method
used to account for it.
Study population and time period
Important questions for any trial are what study populations
should be considered and over what time period. It is likely that
initial cognitive safety studies will be conducted in healthy volun-
teers, which should explore a range of doses over a variety of
timescales. Single dose (acute) or repeated dose (chronic) both
need to be considered, depending on whether the drug in question
is intended for use over an extended period of time.
However, even if studies in healthy volunteers provide results
consistent with cognitive safety, it would still be important to test
the cognitive effects of a drug in patient populations. Indeed, it is
possible that cognition might be adversely affected by a given drug
in healthy volunteers, while in the target patient population
effects on cognition are minor (because the concomitant allevia-
tion of symptoms can have a positive effect on cognitive function).
For example, donepezil is known to impair cognition in healthy
volunteers [48], but nonetheless is approved as a treatment for450 www.drugdiscoverytoday.comdementia. It is also possible that the cognitive effects of a drug
might interact with developmental stage in younger populations
(with potentially important implications for academic attainment
if patients are still studying), or neurodegeneration in older or
cognitively vulnerable individuals. Finally, cognitive effects of
drugs might occur cumulatively, as shown by the example of
anticholinergic load outlined in the introduction; therefore, addi-
tive or interactive effects with other drugs might be important to
consider (Fig. 1). This has important implications for real-world
clinical practice, because clinicians assessing risk and prescribing
need to consider other drugs that their patients might be taking.
Measurement of cognition
Broadly speaking, cognitive assessments measure an individual’s
information processing capacity, including concentration, stor-
age, and control (Fig. 2). The sensitivity and comprehensiveness of
measurement is a crucial consideration in cognitive safety studies,
especially in the common situation that inference will be based on
statistically nonsignificant results. Even in an otherwise adequate-
ly powered study, a misleading nonsignificant result could arise if
an insensitive instrument was used to assess cognition, or was
applied incorrectly. Therefore, it is important to utilise sensitive,
standardised cognitive assessments that have demonstrated sen-
sitivity to cognitive impairment. The measurements used should
also have adequate test–retest reliability and low practice effects to
maximise sensitivity. A common strategy has been to assess cog-
nitive impairment through self-report questionnaires [19]. How-
ever, in many cases, individuals will not have good insight into
their own cognitive ability, so this might be insufficient to exclude
all but the most pronounced effects on cognition.
Choosing appropriate tests for the study population in question
is another important aspect of cognitive safety. If a test is too easy
or too difficult then sensitivity will be compromised because of
measurement boundary effects. For example, a test such as the
MMSE (routinely used in the detection of dementia) will not be
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used should incorporate different levels of difficulty, which might
be adjusted adaptively, furnishing sensitivity to detect cognitive
impairment across the range of ability.
Until the late 1960s, cognitive assessments almost exclusively
used traditional paper-and-pencil measures, many of which were
based on tests originally developed for the US Army to screen
recruits. These tests are still used as part of standardised neuropsy-
chological assessment in clinical settings. However, from the
1970s onwards, investigators began to use computerised testing
to assess the cognitive effects of drugs [23], including automated
versions of earlier paper-and-pencil tests [49] as well as new tests
intended to assess specific domains of cognitive function [24]. The
advent of automated computerised testing saw several improve-
ments in the measurement of cognition. These include: increased
precision of measurement, especially in relation to response speed;
standardised timing of presentation of stimuli; greatly reduced
potential for administrator errors or bias; improved portability;
and increased efficiency (because data do not require digitisation
before analysis). Automated computerised tests also have the
advantage that they can be administered by less specialist staff,
at substantially lower cost. However, despite these advantages,
such cognitive assessments have not been used routinely as safety
assessments during clinical development.
The term ‘cognition’ covers a range of processes, including
(among others) perception, working memory (maintaining infor-
mation ‘on-line’), episodic memory, sustained attention, decision
making, and motor performance. Therefore, it is desirable to
incorporate multiple tests into any assessment (although investi-
gators might decide to focus on cognitive functions likely to be
affected by the particular mechanism of action of the drug). For
example, if memory is not assessed at all during cognitive assess-
ment, then the study cannot draw any conclusions about the
effects of the drug on this process, which might obscure potential
implications for everyday function. Importantly, it is possible that35
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FIGURE 3
Results from a Phase I study of the comparative effect of 5-mg zolpidem (benzodiaz
inverse agonist in development for obesity and/or addiction: middle–right side of
responses, relative to placebo, to approximately the same degree as previously show
points [55]). Even at the highest dose tested, the average impairment caused by 
caused by 5-mg zolpidem, consistent with a relatively low cognitive risk and suppor
placebo.
Source: Reproduced, with permission, from [54].a drug could impair certain cognitive processes while leaving
others intact, resulting in a profile of cognitive impairment. The
use of a range of cognitive measures is also an important statistical
consideration, because it will increase the number of comparisons
made and thereby the false positive rate. One possible solution is
to compute a composite measure across tests, but this approach is
only valid when the tests all assess a common process.
Interpreting a cognitive safety signal
A challenge associated with the assessment of cognition is the
interpretation of any signals observed. In addition to the statistical
methods discussed above, it is important to communicate the
magnitude of any detrimental effects in context. While statisti-
cally significant impairments might be detected, it does not auto-
matically follow that these will be clinically meaningful.
Several possible approaches can be used to decide whether an
effect is clinically meaningful. One would be to determine whether
the estimated effect size of the impairment falls within conven-
tional limits for small, medium or large effects. Following Cohen’s
convention [50], an effect size (SMD) of <0.3 might be considered
small, and might not be clinically meaningful. However, unlike
efficacy studies, in which one might feel comfortable in accepting
effect sizes of SMD < 0.3 as not clinically meaningful, a more risk-
averse perspective might be warranted when considering cognitive
safety. Hence, the criterion for nonclinical relevance might need
to be more stringent; for example, an effect size of SMD < 0.2 or
lower. However, the precise level set would also need to consider
the risk–benefit profile for the drug under study in relation to the
target indication. When incorporating multiple tests to assess
cognition across cognitive domains, the domain or combination
of domains affected might further contribute to the evaluation of
whether an effect is a clinically meaningful. The criterion should
be set proportionately more strictly for indications where the risks
of treatment might outweigh the benefits (e.g., developmental
conditions).5 Day 10 Overall
-20 ms
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observed in neuropsychiatric disorders; for example, impairments
of SMD = 1.5 (or higher) occur in cognitive disorders, such as
dementia or MCI [51]. Schizophrenia and depression, in which
cognitive impairments are considered core symptoms, are associ-
ated with impairments of around SMD = 1 and SMD = 0.5, respec-
tively [52,53]. Typically, SMDs of 0.65 or greater (equivalent to
around a ten-point drop in performance IQ) would be considered
clinically relevant; hence, an impairment of this magnitude would
indicate a clinically significant safety signal.
An alternative approach is to benchmark any observed cogni-
tive safety signals against socially acceptable levels of im-
pairment. In this regard, considering the impairment elicited
by alcohol at the legal driving limit (i.e., 0.05–0.07 g/dL in most
countries), overnight sleep deprivation, or healthy ageing might
be useful. For example, this approach was used in assessing the
safety risk of a novel compound, GSK1521498, in Phase I devel-
opment for obesity/addiction [54] (Fig. 3). In this study, a 5-mg
dose of the sedative drug zolpidem (active comparator), which
causes a decrement in reaction time during sustained concentra-
tion similar to the minimum impairment elicited by alcohol at
0.05 g/dL (approximately 25 ms, SMD approximately 0.7) [55],
was used to examine the cognitive risk associated with
GSK1521498 in a comparative manner. As expected, 5-mg zolpi-
dem caused a significant reaction time impairment (approxi-
mately 25 ms), confirming the sensitivity of the cognitive
measurement and study design. However, most effects of
GSK1521498 on cognition were nonsignificant relative to place-
bo, and those impairments observed were numerically smaller
than that caused by zolpidem (approximately 20 ms averaged
across three time points at the highest dose), indicating a rela-
tively low cognitive safety risk and supporting the continued
clinical development of the compound.452 www.drugdiscoverytoday.comConcluding remarks
Here, we have reviewed the rationale for examining cognitive safety
during clinical development, possible study designs and analytic
approaches, considerations relating to measurement sensitivity,
and strategies for interpreting and communicating any cognitive
safety signals. This field is still at an early stage, and precisely what
designs should be adopted, what outcome measures should be used,
and what statistical approaches are most appropriate will vary
depending on the drug in question and the indication. Although
we have proposed some approaches that might be useful and made
some initial recommendations, there is as yet no consensus on the
best way to demonstrate cognitive safety, or even how this term
should be interpreted. Ultimately, prescribing medication is about
weighing up the potential for risks and benefits. Even if a drug is
shown to induce some cognitive impairment, it might still be
beneficial to prescribe it; but pharmaceutical companies, regulators,
clinicians, and patients need to understand the possible cognitive
risks, and their implications for everyday function.
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